Pfizer and Repligen will develop the latter's spinal muscular atrophy program including experimental SMA drug RG3039 as part of a licensing deal. RG3039, which was licensed from patient advocacy group Families of SMA, holds orphan-drug status in the U.S. and Europe as well as fast-track designation in the U.S. Repligen will receive $5 million upfront and as much as $65 million in milestone fees plus royalties.

Related Summaries